RT Journal Article
T1 Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
A1 Sánchez Montero, José
A1 González Matilla, Juan Francisco
A1 Alcántara León, Andrés Rafael
A1 Doadrio Villarejo, Antonio Luis
AB Introduction: Alzheimer’s disease (AD), the most common type of dementia among older adults, is a chronic neurodegenerative pathology that causes a progressive loss of cognitive functioning with a decline of rational skills. It is well known that AD is multifactorial, so there are many different pharmacological targets that can be pursued.Areas covered: The authors highlight the strategic value of privileged scaffolds in a multi-target lead compound generation against AD, exploring the concept of multi-target design, with a special emphasis on hybrid compounds. Hence, the most promising building blocks for designing and synthesizing hybrid anti-AD drugs are shown, while also presenting the more advanced hybrid compounds.Expert opinion: The available therapeutic arsenal for AD, designed under the traditional paradigm of ‘one-drug/one target/one-disease’, is based on the inhibition of brain acetylcholinesterase (AChE) to increase acetylcholine (ACh) levels. However, this classical approach has not been sufficiently effective when used to treat any multifactor-depending pathology (cancer, diabetes or AD). The multi-target drug concept has been quickly adopted by medicinal chemists. The basic research developments reported in recent years are a solid foundation that will pave the way for the construction of future AD therapeutics.
PB Taylor and Francis
SN 1746-0441
YR 2019
FD 2019-06-05
LK https://hdl.handle.net/20.500.14352/92533
UL https://hdl.handle.net/20.500.14352/92533
LA eng
NO González Juan F,  Alcántara Andrés R.,  Doadrio Antonio L.,   Sánchez-Montero Jose María. Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches, Expert Opinion on Drug Discovery, 2019 Jun 14:9, 879-91
NO Este trabajo fue realizado por invitación expresa de la editorial Taylor and Francis sin coste alguno para los autores
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Universidad Complutense de Madrid
NO Banco Santander
DS Docta Complutense
RD 22 abr 2025